1
|
Ye F, Wang C, O’Connor AM. OssaNMA: An R package for using information from network meta-analyses to optimize the power and sample allocation of a new two-arm trial. PLoS One 2023; 18:e0296020. [PMID: 38128003 PMCID: PMC10734972 DOI: 10.1371/journal.pone.0296020] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/17/2023] [Accepted: 12/04/2023] [Indexed: 12/23/2023] Open
Abstract
Randomized clinical trials (RCTs) are designed for measuring the effectiveness of the treatments and testing a hypothesis regarding the relative effect between two or more treatments. Trial designers are often interested in maximizing power when the total sample size is fixed or minimizing the required total sample size to reach a pre-specified power. One approach to maximizing power proposed by previous researchers is to leverage prior evidence using meta-analysis (NMA) to inform the sample size determination of a new trial. For example, researchers may be interested in designing a two-arm trial comparing treatments A and B which are already in the existing trial network but do not have any direct comparison. The researchers' intention is to incorporate the result into an existing network for meta-analysis. Here we develop formulas to address these options and use simulations to validate our formula and evaluate the performance of different analysis methods in terms of power. We also implement our proposed method into the R package OssaNMA and publish an R Shiny app for the convenience of the application. The goal of the package is to enable researchers to readily adopt the proposed approach which can improve the power of an RCT and is therefore resource-saving. In the R Shiny app, We also provide the option to include the cost of each treatment which would enable researchers to compare the total treatment cost associated with each design and analysis approach. Further, we explore the effect of allocation to treatment group on study power when the a priori plan is to incorporate the new trial result into an existing network for meta-analysis.
Collapse
Affiliation(s)
- Fangshu Ye
- Department of Statistics, Iowa State University, Ames, Iowa, United States of America
| | - Chong Wang
- Department of Statistics, Iowa State University, Ames, Iowa, United States of America
- Department of Veterinary Diagnostics and Production Animal Medicine, Iowa State University, Ames, Iowa, United States of America
| | - Annette M. O’Connor
- Department of Veterinary Diagnostics and Production Animal Medicine, Iowa State University, Ames, Iowa, United States of America
- Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, Michigan, United States of America
| |
Collapse
|
2
|
Ye F, Wang C, O'Connor AM. Optimal trial design selection: a comparative analysis between two-arm and three-arm trials incorporating network meta-analysis for evaluating a new treatment. BMC Med Res Methodol 2023; 23:267. [PMID: 37951877 PMCID: PMC10638718 DOI: 10.1186/s12874-023-02089-y] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/27/2023] [Accepted: 11/01/2023] [Indexed: 11/14/2023] Open
Abstract
BACKGROUND Planning the design of a new trial comparing two treatments already in a network of trials with an a-priori plan to estimate the effect size using a network meta-analysis increases power or reduces the sample size requirements. However, when the comparison of interest is between a treatment already in the existing network (old treatment) and a treatment that hasn't been studied previously (new treatment), the impact of leveraging information from the existing network to inform trial design has not been extensively investigated. We aim to identify the most powerful trial design for a comparison of interest between an old treatment A and a new treatment Z, given a fixed total sample size. We consider three possible designs: a two-arm trial between A and Z ('direct two-arm'), a two-arm trial between another old treatment B and Z ('indirect two-arm'), and a three-arm trial among A, B, and Z. METHODS We compare the standard error of the estimated effect size between treatments A and Z for each of the three trial designs using formulas. For continuous outcomes, the direct two-arm trial always has the largest power, while for a binary outcome, the minimum variances among the three trial designs are conclusive only when [Formula: see text]. Simulation studies are conducted to demonstrate the potential for the indirect two-arm and three-arm trials to outperform the direct two-arm trial in terms of power under the condition of [Formula: see text]. RESULTS Based on the simulation results, we observe that the indirect two-arm and three-arm trials have the potential to be more powerful than a direct two-arm trial only when [Formula: see text]. This power advantage is influenced by various factors, including the risk of the three treatments, the total sample size, and the standard error of the estimated effect size from the existing network meta-analysis. CONCLUSIONS The standard two-arm trial design between two treatments in the comparison of interest may not always be the most powerful design. Utilizing information from the existing network meta-analysis, incorporating an additional old treatment into the trial design through an indirect two-arm trial or a three-arm trial can increase power.
Collapse
Affiliation(s)
- Fangshu Ye
- Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA, USA
| | - Chong Wang
- Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA, USA.
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.
| | - Annette M O'Connor
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| |
Collapse
|
3
|
Mackey SJ, Cooke RF, Colombo EA, Pickett AT, Batista LFD, Block E, Brandâo AP. Supplementing pre- and probiotic ingredients to feedlot steers: effects on health, growth performance, and physiological responses. Animal 2023; 17:100770. [PMID: 37031589 DOI: 10.1016/j.animal.2023.100770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2022] [Revised: 02/28/2023] [Accepted: 03/02/2023] [Indexed: 03/16/2023] Open
Abstract
Feedlot diets are often enriched with additives to mitigate health disorders and promote cattle performance, including the feed-grade antimicrobials monensin and tylosin. However, alternative feeding strategies are warranted given the increasing regulations regarding the use of antimicrobials in feedlot diets. This study evaluated the performance, physiological, and health responses of feedlot cattle offered a synbiotic supplement (yeast-derived prebiotic + Bacillus subtilis probiotic), which replaced or was fed in conjunction with monensin and tylosin. Angus-influenced steers (n = 192) from four different cowherds were weaned on day -1 and transported (800 km) to the feedlot. Steers were allocated to 1 of 24 pens (eight steers/pen) upon arrival on day 0. Pens were assigned to receive (n = 8/treatment) a total-mixed ration (TMR) containing: (1) monensin and tylosin (RT; 360 mg/steer daily from Rumensin and 90 mg/steer daily from Tylan; Elanco Animal Health, Greenfield, IN, USA), (2) yeast-derived ingredient and B. subtilis probiotic (CC; 18 g/steer daily of Celmanax and 28 g/steer daily of Certillus; Church and Dwight Co., Inc., Princeton, NJ, USA), or (3) a combination of RT and CC (RTCC). Steers were slaughtered according to BW in four groups balanced by treatment and pens and received treatments for 252 ± 4 days. No treatment effects were detected (P ≥ 0.17) for steer BW gain and morbidity responses. Mean TMR intake was greater and gain:feed ratio was less (P ≤ 0.01) in CC compared with RT and RTCC steers. Mean plasma leptin concentration was greater (P ≤ 0.05) in CC compared with RT and RTCC steers. Steers receiving CC had greater (P ≤ 0.04) concentrations of plasma cortisol, haptoglobin, glucose, and beta-hydroxybutyrate, and less (P ≤ 0.05) concentration of non-esterified fatty acids compared with RT and RTCC steers on day 14 of the experiment. Carcass marbling was greater (P = 0.01) in CC compared with RT steers and tended to be greater (P = 0.07) in RTCC compared with RT steers. Proportion of carcasses that graded Choice or better and Longissimus muscle area were greater (P ≤ 0.05) in CC and RTCC compared with RT steers. Incidence of liver abscesses was less (P = 0.01) in RTCC compared with CC steers and tended to be less (P = 0.09) in RT compared with CC steers. Results from this experiment indicate that the synbiotic supplement may replace monensin and tylosin without reducing steer BW gain, with potential improvements to carcass quality traits.
Collapse
Affiliation(s)
- S J Mackey
- Texas A&M University - Department of Animal Science, College Station, TX 77845, USA
| | - R F Cooke
- Texas A&M University - Department of Animal Science, College Station, TX 77845, USA.
| | - E A Colombo
- Texas A&M University - Department of Animal Science, College Station, TX 77845, USA
| | - A T Pickett
- Texas A&M University - Department of Animal Science, College Station, TX 77845, USA
| | - L F D Batista
- Texas A&M University - Department of Animal Science, College Station, TX 77845, USA
| | - E Block
- Arm & Hammer Animal and Food Production - Church & Dwight Co. Inc., Princeton, NJ 08543, USA
| | - A P Brandâo
- Texas A&M University - Department of Animal Science, College Station, TX 77845, USA
| |
Collapse
|
4
|
Horton LM, Depenbusch BE, Dewsbury DM, McAtee TB, Betts NB, Renter DG. Comprehensive Outcomes Affected by Antimicrobial Metaphylaxis of Feedlot Calves at Medium-Risk for Bovine Respiratory Disease from a Randomized Controlled Trial. Vet Sci 2023; 10:vetsci10020067. [PMID: 36851371 PMCID: PMC9960805 DOI: 10.3390/vetsci10020067] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/29/2022] [Revised: 12/26/2022] [Accepted: 01/14/2023] [Indexed: 01/18/2023] Open
Abstract
The objectives were to evaluate the effects of metaphylaxis (META) and pull-and-treat (PT) programs on health, antimicrobial use, beef production, economics, and greenhouse gas emissions in cattle at medium risk for bovine respiratory disease (BRD). A randomized complete block design was used at two US commercial feedlots. Steers and heifers [2366 total; 261 (±11.0) kg initial weight] were blocked by sex and feedlot arrival, and allocated to one of two pens within a block (16 pens total, eight blocks). Pens were randomly assigned to treatment: META, tulathromycin injection at initial processing; or PT, tulathromycin injection only for first clinical BRD treatment. Data were analyzed with linear and generalized linear mixed models. There was greater BRD morbidity in PT than META cattle (17.2% vs. 7.3% respectively; p < 0.01), and greater total mortality (2.5% vs. 1.1% respectively; p = 0.03). Per animal enrolled, 1.1 antimicrobial doses were used for META compared to 0.2 for PT (p < 0.01). Per animal enrolled, final live (p = 0.04) and carcass (p = 0.08) weights were greater for META than PT; however, net returns ($/animal) were not significantly different (p = 0.71). Compared to PT, total lifetime estimated CO2 equivalent emissions from production were reduced by 2% per unit of live weight for META (p = 0.09). While antimicrobial use was reduced with PT, there may be substantial negative impacts on other outcomes if META was not used in this type of cattle population.
Collapse
Affiliation(s)
- Lucas M. Horton
- The Center for Outcomes Research and Epidemiology, Department of Diagnostic Medicine and Pathobiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA
| | | | - Diana M. Dewsbury
- The Center for Outcomes Research and Epidemiology, Department of Diagnostic Medicine and Pathobiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA
| | - Taylor B. McAtee
- The Center for Outcomes Research and Epidemiology, Department of Diagnostic Medicine and Pathobiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA
| | | | - David G. Renter
- The Center for Outcomes Research and Epidemiology, Department of Diagnostic Medicine and Pathobiology, Kansas State University College of Veterinary Medicine, Manhattan, KS 66506, USA
- Correspondence:
| |
Collapse
|
5
|
Ye F, Wang C, O’Connor AM. When we shouldn't borrow information from an existing network of trials for planning a new trial. Front Pharmacol 2023; 14:1157708. [PMID: 37188261 PMCID: PMC10176253 DOI: 10.3389/fphar.2023.1157708] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/04/2023] [Accepted: 04/18/2023] [Indexed: 05/17/2023] Open
Abstract
Introduction: To achieve higher power or increased precision for a new trial, methods based on updating network meta-analysis (NMA) have been proposed by researchers. However, this approach could potentially lead to misinterpreted results and misstated conclusions. This work aims to investigate the potential inflation of type I error risk when a new trial is conducted only when, based on a p-value of the comparison in the existing network, a "promising" difference between two treatments is noticed. Methods: We use simulations to evaluate the scenarios of interest. In particular, a new trial is to be conducted independently or depending on the results from previous NMA in various scenarios. Three analysis methods are applied to each simulation scenario: with the existing network, sequential analysis and without the existing network. Results: For the scenario that the new trial will be conducted only when a promising finding (p-value <5%) is indicated by the existing network, the type I error risk increased dramatically (38.5% in our example data) when analyzed with the existing network and sequential analysis. The type I error is controlled at 5% when analyzing the new trial without the existing network. Conclusion: If the intention is to combine a trial result with an existing network of evidence, or if it is expected that the trial will eventually be included in a network meta-analysis, then the decision that a new trial is performed should not depend on a statistically "promising" finding indicated by the existing network.
Collapse
Affiliation(s)
- Fangshu Ye
- Department of Statistics, Iowa State University, Ames, IA, United States
| | - Chong Wang
- Department of Statistics, Iowa State University, Ames, IA, United States
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, United States
- *Correspondence: Chong Wang,
| | - Annette M. O’Connor
- Department of Veterinary Diagnostic and Production Animal Medicine, Iowa State University, Ames, IA, United States
- Department of Large Animal Clinical Sciences, Michigan State University, East Lansing, MI, United States
| |
Collapse
|
6
|
Hu D, Wang C, Ye F, O’Connor AM. Using information from network meta-analyses to optimize the power and sample allocation of a subsequent trial with a new treatment. BMC Med Res Methodol 2022; 22:299. [PMID: 36418960 PMCID: PMC9682784 DOI: 10.1186/s12874-022-01792-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/04/2022] [Accepted: 11/11/2022] [Indexed: 11/24/2022] Open
Abstract
BACKGROUND A critical step in trial design is determining the sample size and sample allocation to ensure the proposed study has sufficient power to test the hypothesis of interest: superiority, equivalence, or non-inferiority. When data are available from prior trials and leveraged with the new trial to answer the scientific questions, the value of society's investment in prior research is increased. When prior information is available, the trial design including the sample size and allocation should be adapted accordingly, yet the current approach to trial design does not utilize such information. Ensuring we maximize the value of prior research is essential as there are always constraints on resources, either physical or financial, and designing a trial with adequate power can be a challenge. METHODS We propose an approach to increasing the power of a new trial by incorporating evidence from a network meta-analysis into the new trial design and analysis. We illustrate the methodology through an example network meta-analysis, where the goal is to identify the optimal allocation ratio for the new three-arm trial, which involves the reference treatment, the new treatment, and the negative control. The primary goal of the new trial is to show that the new treatment is non-inferior to the reference treatment. It may also be of interest to know if the new treatment is superior to the negative control. We propose an optimal treatment allocation strategy which is derived from minimizing the standard error of the log odds ratio estimate of the comparison of interest. We conducted a simulation study to assess the proposed methods to design a new trial while borrowing information from the existing network meta-analysis and compare it to even allocation methods. RESULTS Using mathematical derivation and simulations, we document that our proposed approach can borrow information from a network meta-analysis to modify the treatment allocation ratio and increase the power of the new trial given a fixed total sample size or to reduce the total sample size needed to reach a desired power. CONCLUSIONS When prior evidence about the hypotheses of interest is available, the traditional equal allocation strategy is not the most powerful approach anymore. Our proposed methodology can improve the power of trial design, reduce the cost of trials, and maximize the utility of prior investments in research.
Collapse
Affiliation(s)
- Dapeng Hu
- grid.34421.300000 0004 1936 7312Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA United States of America
| | - Chong Wang
- grid.34421.300000 0004 1936 7312Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA United States of America ,grid.34421.300000 0004 1936 7312Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA United States of America
| | - Fangshu Ye
- grid.34421.300000 0004 1936 7312Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA United States of America
| | - Annette M. O’Connor
- grid.34421.300000 0004 1936 7312Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA United States of America ,grid.17088.360000 0001 2150 1785Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI United States of America
| |
Collapse
|
7
|
Cummings DB, Meyer NF, Step DL. Bovine Respiratory Disease Considerations in Young Dairy Calves. Vet Clin North Am Food Anim Pract 2022; 38:93-105. [PMID: 35219488 DOI: 10.1016/j.cvfa.2021.11.007] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
Abstract
Raising young dairy calves presents many challenges for producers and veterinarians including losses attributable to BRD. This article will discuss several key concepts for practitioners to consider when applying evidence-based medicine for the control and treatment of BRD in young dairy calves. The authors review BRD complex, provide considerations for diagnostic approaches, and discuss research associated with the control and treatment of BRD.
Collapse
Affiliation(s)
- Daniel B Cummings
- Boehringer Ingelheim Animal Health USA Inc., 3239 Satellite Blvd., Duluth, GA, 30096.
| | - Nathan F Meyer
- Boehringer Ingelheim Animal Health USA Inc., 3239 Satellite Blvd., Duluth, GA, 30096; Affiliate Faculty, Department of Clinical Sciences, Colorado State University, 1601 Campus Delivery, Fort Collins, CO, 80523
| | - Douglas L Step
- Boehringer Ingelheim Animal Health USA Inc., 3239 Satellite Blvd., Duluth, GA, 30096
| |
Collapse
|
8
|
Sarchet JJ, Pollreisz JP, Bechtol DT, Blanding MR, Saltman RL, Taube PC. Limitations of bacterial culture, viral PCR, and tulathromycin susceptibility from upper respiratory tract samples in predicting clinical outcome of tulathromycin control or treatment of bovine respiratory disease in high-risk feeder heifers. PLoS One 2022; 17:e0247213. [PMID: 35143504 PMCID: PMC8830659 DOI: 10.1371/journal.pone.0247213] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2021] [Accepted: 01/09/2022] [Indexed: 01/08/2023] Open
Abstract
A cross-sectional prospective cohort study including 1026 heifers administered tulathromycin due to high risk of clinical signs of bovine respiratory disease (BRD), measured poor association between BRD clinical outcomes and results of bacterial culture and tulathromycin susceptibility from BRD isolates of deep nasopharyngeal swabs (DNS) and adequate association with viral polymerase chain reaction (PCR) results from nasal swabs. Isolation rates from DNS collected on day-0 and at 1st BRD-treatment respectively were: Mannheimia haemolytica (10.9% & 34.1%); Pasteurella multocida (10.4% & 7.4%); Mycoplasma bovis (1.0% & 36.6%); and Histophilus somni (0.7% & 6.3%). Prevalence of BRD viral nucleic acid on nasal swabs collected exclusively at 1st BRD-treatment were: bovine parainfluenza virus type-3 (bPIV-3) 34.1%; bovine viral diarrhea virus (BVDV) 26.3%; bovine herpes virus type-1 (BHV-1) 10.8%; and bovine respiratory syncytial virus (BRSV) 54.1%. Increased relative risk, at 95% confidence intervals, of 1st BRD-treatment failure was associated with positive viral PCR results: BVDV 1.39 (1.17-1.66), bPIV-3 1.26 (1.06-1.51), BHV-1 1.52 (1.25-1.83), and BRSV 1.35 (1.11-1.63) from nasal swabs collected at 1st BRD-treatment and culture of M. haemolytica 1.23 (1.00-1.51) from DNS collected at day-0. However, in this population of high-risk feeder heifers, the predictive values of susceptible and resistant isolates had inadequate association with BRD clinical outcome. These results indicate, that using tulathromycin susceptibility testing of isolates of M. haemolytica or P. multocida from DNS collected on arrival or at 1st BRD-treatment to evaluate tulathromycin clinical efficacy, is unreliable.
Collapse
MESH Headings
- Animals
- Anti-Bacterial Agents/pharmacology
- Anti-Bacterial Agents/therapeutic use
- Bovine Respiratory Disease Complex/drug therapy
- Bovine Respiratory Disease Complex/microbiology
- Bovine Respiratory Disease Complex/pathology
- Cattle
- Cattle Diseases/drug therapy
- Cattle Diseases/microbiology
- Cattle Diseases/pathology
- Cross-Sectional Studies
- DNA, Viral/genetics
- DNA, Viral/metabolism
- Diarrhea Viruses, Bovine Viral/drug effects
- Diarrhea Viruses, Bovine Viral/genetics
- Diarrhea Viruses, Bovine Viral/isolation & purification
- Disaccharides/pharmacology
- Disaccharides/therapeutic use
- Herpesvirus 1, Bovine/drug effects
- Herpesvirus 1, Bovine/genetics
- Herpesvirus 1, Bovine/isolation & purification
- Heterocyclic Compounds/pharmacology
- Heterocyclic Compounds/therapeutic use
- Mannheimia haemolytica/drug effects
- Mannheimia haemolytica/isolation & purification
- Microbial Sensitivity Tests
- Nasopharynx/microbiology
- Nasopharynx/virology
- Pasteurella multocida/drug effects
- Pasteurella multocida/isolation & purification
- Polymerase Chain Reaction
- Prospective Studies
- RNA, Viral/genetics
- RNA, Viral/metabolism
- Respiratory Syncytial Virus, Bovine/drug effects
- Respiratory Syncytial Virus, Bovine/genetics
- Respiratory Syncytial Virus, Bovine/isolation & purification
- Risk Factors
- Treatment Failure
Collapse
Affiliation(s)
- Jeffrey J. Sarchet
- Zoetis, Parsippany-Troy Hills, New Jersey, United States of America
- * E-mail:
| | | | | | | | - Roger L. Saltman
- Zoetis, Parsippany-Troy Hills, New Jersey, United States of America
| | - Patrick C. Taube
- Zoetis, Parsippany-Troy Hills, New Jersey, United States of America
| |
Collapse
|
9
|
Cernicchiaro N, Oliveira ARS, Hanthorn C, Renter DG. Outcomes research: origins, relevance, and potential impacts for veterinary medicine. J Am Vet Med Assoc 2022; 260:714-723. [DOI: 10.2460/javma.21.06.0318] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Affiliation(s)
- Natalia Cernicchiaro
- Center for Outcomes Research and Epidemiology (CORE), College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - Ana R. S. Oliveira
- Center for Outcomes Research and Epidemiology (CORE), College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - Christy Hanthorn
- Center for Outcomes Research and Epidemiology (CORE), College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - David G. Renter
- Center for Outcomes Research and Epidemiology (CORE), College of Veterinary Medicine, Kansas State University, Manhattan, KS
| |
Collapse
|
10
|
Hu D, Wang C, O'Connor AM. A likelihood ratio test for the homogeneity of between-study variance in network meta-analysis. Syst Rev 2021; 10:310. [PMID: 34886897 PMCID: PMC8662889 DOI: 10.1186/s13643-021-01859-3] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/10/2021] [Accepted: 11/18/2021] [Indexed: 11/21/2022] Open
Abstract
BACKGROUND Network meta-analysis (NMA) is a statistical method used to combine results from several clinical trials and simultaneously compare multiple treatments using direct and indirect evidence. Statistical heterogeneity is a characteristic describing the variability in the intervention effects being evaluated in the different studies in network meta-analysis. One approach to dealing with statistical heterogeneity is to perform a random effects network meta-analysis that incorporates a between-study variance into the statistical model. A common assumption in the random effects model for network meta-analysis is the homogeneity of between-study variance across all interventions. However, there are applications of NMA where the single between-study assumption is potentially incorrect and instead the model should incorporate more than one between-study variances. METHODS In this paper, we develop an approach to testing the homogeneity of between-study variance assumption based on a likelihood ratio test. A simulation study was conducted to assess the type I error and power of the proposed test. This method is then applied to a network meta-analysis of antibiotic treatments for Bovine respiratory disease (BRD). RESULTS The type I error rate was well controlled in the Monte Carlo simulation. We found statistical evidence (p value = 0.052) against the homogeneous between-study variance assumption in the network meta-analysis BRD. The point estimate and confidence interval of relative effect sizes are strongly influenced by this assumption. CONCLUSIONS Since homogeneous between-study variance assumption is a strong assumption, it is crucial to test the validity of this assumption before conducting a network meta-analysis. Here we propose and validate a method for testing this single between-study variance assumption which is widely used for many NMA.
Collapse
Affiliation(s)
- Dapeng Hu
- Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA, USA
| | - Chong Wang
- Department of Statistics, College of Liberal Arts and Sciences, Iowa State University, Ames, IA, USA. .,Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.
| | - Annette M O'Connor
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, USA.,Professor of Epidemiology, Chairperson of the Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, USA
| |
Collapse
|
11
|
Ma T, McAllister TA, Guan LL. A review of the resistome within the digestive tract of livestock. J Anim Sci Biotechnol 2021; 12:121. [PMID: 34763729 PMCID: PMC8588621 DOI: 10.1186/s40104-021-00643-6] [Citation(s) in RCA: 12] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/01/2021] [Accepted: 10/07/2021] [Indexed: 12/25/2022] Open
Abstract
Antimicrobials have been widely used to prevent and treat infectious diseases and promote growth in food-production animals. However, the occurrence of antimicrobial resistance poses a huge threat to public and animal health, especially in less developed countries where food-producing animals often intermingle with humans. To limit the spread of antimicrobial resistance from food-production animals to humans and the environment, it is essential to have a comprehensive knowledge of the role of the resistome in antimicrobial resistance (AMR), The resistome refers to the collection of all antimicrobial resistance genes associated with microbiota in a given environment. The dense microbiota in the digestive tract is known to harbour one of the most diverse resistomes in nature. Studies of the resistome in the digestive tract of humans and animals are increasing exponentially as a result of advancements in next-generation sequencing and the expansion of bioinformatic resources/tools to identify and describe the resistome. In this review, we outline the various tools/bioinformatic pipelines currently available to characterize and understand the nature of the intestinal resistome of swine, poultry, and ruminants. We then propose future research directions including analysis of resistome using long-read sequencing, investigation in the role of mobile genetic elements in the expression, function and transmission of AMR. This review outlines the current knowledge and approaches to studying the resistome in food-producing animals and sheds light on future strategies to reduce antimicrobial usage and control the spread of AMR both within and from livestock production systems.
Collapse
Affiliation(s)
- Tao Ma
- Key laboratory of Feed Biotechnology of the Ministry of Agriculture, Institute of Feed Research, Chinese Academy of Agricultural Sciences, Beijing, 100081, China.,Department of Agricultural, Food and Nutritional Science, University of Alberta, T6G2P5, Edmonton, AB, Canada
| | - Tim A McAllister
- Lethbridge Research and Development Centre, Lethbridge, AB, T1J 4P4, Canada
| | - Le Luo Guan
- Department of Agricultural, Food and Nutritional Science, University of Alberta, T6G2P5, Edmonton, AB, Canada.
| |
Collapse
|
12
|
Lu Q, Xu X, Song S, Wu A, Liu L, Kuang H, Xu C. Development of an Immunochromatographic Strip for the Rapid and Ultrasensitive Detection of Gamithromycin. FOOD ANAL METHOD 2021. [DOI: 10.1007/s12161-021-02146-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
13
|
De Koster J, Tena JK, Stegemann MR. Treatment of bovine respiratory disease with a single administration of tulathromycin and ketoprofen. Vet Rec 2021; 190:e834. [PMID: 34476817 DOI: 10.1002/vetr.834] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/27/2020] [Revised: 05/18/2021] [Accepted: 07/27/2021] [Indexed: 11/05/2022]
Abstract
BACKGROUND The therapeutic strategy of bovine respiratory disease (BRD) often involves a combination of an antibiotic with an anti-inflammatory agent. Aim of this study was to evaluate the clinical effect of a new combination product containing tulathromycin and ketoprofen for the treatment of naturally occurring BRD. METHODS Two hundred and eighty animals were randomized upon diagnosis of BRD. One hundred forty animals each were treated once subcutaneously with tulathromycin-ketoprofen or tulathromycin. Rectal temperature of each animal was measured at 1, 2, 4, 6, 8, 10, 12 and 24 h post-treatment. Individual respiration and depression scores were determined at 6 h post-treatment. Daily rectal temperature, respiration and depression scores were recorded from day 2 to 14 and on day 21. RESULTS The tulathromycin-ketoprofen and tulathromycin treatment group demonstrated a treatment success rate of 94.2% and 95.0%, respectively and a relapse rate of 3.8% and 4.0%, respectively. Tulathromycin-ketoprofen demonstrated superior pyrexia control compared to tulathromycin within the first 24 h following treatment. Tulathromycin-ketoprofen-treated animals demonstrated faster improvement of their clinical symptoms (respiration and depression score). CONCLUSION Efficacy of tulathromycin-ketoprofen for the treatment of BRD was non-inferior to tulathromycin. The combination product clearly exhibited more pronounced fever control than tulathromycin which is considered beneficial for animal welfare.
Collapse
Affiliation(s)
- Jenne De Koster
- Veterinary Medicine Research and Development, Zoetis, Zaventem, Belgium
| | - Jezaniah-Kira Tena
- Veterinary Medicine Research and Development, Zoetis, Kalamazoo, Michigan, USA
| | | |
Collapse
|
14
|
Trott DJ, Turnidge J, Kovac JH, Simjee S, Wilson D, Watts J. Comparative macrolide use in humans and animals: should macrolides be moved off the World Health Organisation's critically important antimicrobial list? J Antimicrob Chemother 2021; 76:1955-1961. [PMID: 33956974 DOI: 10.1093/jac/dkab120] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Macrolide antibiotics are categorized by the WHO as Highest Priority, Critically Important Antimicrobials due to their recommendation as treatment for severe cases of campylobacteriosis in humans; a self-limiting, rarely life-threatening, zoonotic foodborne infection. Low rates of macrolide resistance in Campylobacter jejuni and the availability of alternative treatments have prompted some regulatory schemes to assign macrolides to a lower importance category. Apart from rare, specific infections, macrolides largely play a supportive role to other drug classes in human medicine. By contrast, although the advent of alternative control methods has seen significant reductions in macrolide use in intensive livestock, they still have a crucial role in the treatment/control of respiratory infections and liver abscesses in cattle. Whilst acknowledging that ongoing surveillance is required to reduce the spread of recently emerged, transferable macrolide resistance among Campylobacter, this article recommends that macrolides should be moved to the WHO Highly Important category.
Collapse
Affiliation(s)
- Darren J Trott
- Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, Australia
| | - John Turnidge
- Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, Australia
| | - Jessica H Kovac
- Australian Centre for Antimicrobial Resistance Ecology, School of Animal and Veterinary Sciences, The University of Adelaide, Roseworthy, South Australia, Australia
| | - Shabbir Simjee
- Elanco Animal Health, Form 2, Bartley Way, Bartley Wood Business Park, Hook, England
| | - Danny Wilson
- Research Centre for Infectious Diseases, School of Biological Sciences, University of Adelaide, South Australia, Australia
| | - Jeffrey Watts
- Veterinary Medicine Research and Development, Zoetis, Inc, Kalamazoo, MI, USA
| |
Collapse
|
15
|
Yan Y, Zhang H, Ai L, Kang W, Lian K, Wang J. Determination of gamithromycin residues in eggs, milk and edible tissue of food-producing animals by solid phase extraction combined with ultrahigh-performance liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2021; 1171:122637. [PMID: 33735805 DOI: 10.1016/j.jchromb.2021.122637] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2020] [Revised: 02/24/2021] [Accepted: 02/25/2021] [Indexed: 10/21/2022]
Abstract
A high throughput method was developed and validated for the quantitation of gamithromycin residues in eggs, milk and animal tissues (leg muscle, kidney, liver and fat) of different species and genera. This was undertaken using ultrahigh-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS). The samples were extracted with acetonitrile and purified using an Oasis MCX solid phase extraction cartridge. Subsequently, a C18 column was used for chromatographic separation using acetonitrile and 0.1% formic acid as the mobile phase. LC-MS/MS in positive ESI and multiple reaction monitoring mode with gamithromycin-D4 as the internal standard was used for detection and quantification of gamithromycin. The method was successfully calibrated in the range of 1.0-200 µg/kg. The limit of detection (LOD) and limit of quantification (LOQ) for gamithromycin was 0.30-0.40 µg/kg and 0.80 - 1.0 µg/kg, respectively. The average recoveries of the analyte fortified at three levels ranged from 84.2% to 115.9%, with a relative standard deviation <10%. The proposed method has been successfully used to monitor real samples, and shown to be sensitive, rapid, and convenient. Hence, this method could be used for regulatory purposes to screen for the presence of gamithromycin residues in eggs, milk and target tissues.
Collapse
Affiliation(s)
- Yonghuan Yan
- Department of Sanitary Inspection, School of Public Health, Hebei Medical University, Shijiazhuang 050017, China
| | - Haichao Zhang
- Technology Center of Shijiazhuang Customs, Shijiazhuang 050051, China
| | - Lianfeng Ai
- Technology Center of Shijiazhuang Customs, Shijiazhuang 050051, China.
| | - Weijun Kang
- Department of Sanitary Inspection, School of Public Health, Hebei Medical University, Shijiazhuang 050017, China
| | - Kaoqi Lian
- Department of Sanitary Inspection, School of Public Health, Hebei Medical University, Shijiazhuang 050017, China; Hebei Province Key Laboratory of Environment and Human Health, Hebei Medical University, Shijiazhuang 050017, China.
| | - Jing Wang
- Technology Center of Shijiazhuang Customs, Shijiazhuang 050051, China
| |
Collapse
|
16
|
Buczinski S, Achard D, Timsit E. Effects of calfhood respiratory disease on health and performance of dairy cattle: A systematic review and meta-analysis. J Dairy Sci 2021; 104:8214-8227. [PMID: 33896639 DOI: 10.3168/jds.2020-19941] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/22/2020] [Accepted: 03/19/2021] [Indexed: 12/13/2022]
Abstract
Bovine respiratory disease (BRD) is one of the most common calfhood diseases in dairy cattle. Unfortunately, published data on the short- and long-term effects of calfhood BRD on health and performance are scarce and, when available, often conflicting and uncertain. The objective of this study was therefore to review the scientific literature on the effects of calfhood BRD on health and performance of dairy cattle and summarize the research findings using a meta-analysis approach. The systematic review and meta-analysis were performed following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. PubMed and CAB Abstract databases were screened for relevant studies that were published in English (until February 3, 2020). Only studies reporting naturally occurring BRD cases from birth to 12 mo of age in dairy calves in Europe and North America were considered eligible. Both observational studies and randomized controlled trials were included. Random-effect meta-analysis models were used to quantify the effect of BRD on outcomes for which at least 5 studies reported a numeric estimation of the effect of BRD. From an initial pool of 525 references, 27 full-text articles with original data were included in the manuscript. Meta-analysis models were prepared for 4 outcomes: odds of mortality (n = 7 studies), odds of herd removal before first calving (n = 5 studies), average daily gain (n = 10 studies), and milk production during first lactation (n = 5 studies). In these models, heifers diagnosed with BRD during calfhood had 2.85 times higher odds of dying (95% confidence interval: 1.22 to 6.69) and 2.30 times higher odds of herd removal (i.e., dead, culled, or sold) before the first calving (95% confidence interval: 1.75 to 3.03) compared with heifers not diagnosed with this condition. Heifers experiencing calfhood BRD also had an average daily gain reduced by 0.067 kg/d (95% confidence interval: -0.099 to -0.034) and they produced 121.2 kg (95% confidence interval: -184.9 to -57.5) less milk during their first lactation. Other health and performance outcomes, such as age at first calving and odds of not finishing the first lactation, were also investigated but not summarized using a meta-analysis approach. Pooled estimates obtained in the present study may provide more accurate estimates of the overall economic losses associated with calfhood BRD in dairy cattle.
Collapse
Affiliation(s)
- S Buczinski
- Département des Sciences Cliniques, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC, Canada J2S 2M2; Centre d'expertise et de recherche clinique en santé et bien-être animal, Faculté de Médecine Vétérinaire, Université de Montréal, St-Hyacinthe, QC, Canada J2S 2M2.
| | - D Achard
- Ceva Santé Animale, Libourne, France 33100
| | - E Timsit
- Ceva Santé Animale, Libourne, France 33100; Department of Production Animal Health, Faculty of Veterinary Medicine, University of Calgary, AB, Canada T2N 4N1.
| |
Collapse
|
17
|
da Silva CF, Almeida T, de Melo Barbosa R, Cardoso JC, Morsink M, Souto EB, Severino P. New Trends in Drug Delivery Systems for Veterinary Applications. Pharm Nanotechnol 2021; 9:15-25. [PMID: 32533821 DOI: 10.2174/2211738508666200613214548] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/08/2020] [Revised: 04/24/2020] [Accepted: 05/04/2020] [Indexed: 11/22/2022]
Abstract
BACKGROUND The veterinary pharmaceutical industry has shown significant growth in recent decades. Several factors contribute to this increase as the demand for the improvement of the quality of life of both domestic and wild animals, together with the need to improve the quality, productivity, and safety of foodstuffs of animal origin. METHODS The goal of this work was to identify the most suitable medicines for animals that focus on drug delivery routes as those for humans, although they may have different devices, such as collars and ear tags. RESULTS Recent advances in drug delivery systems for veterinary use are discussed, both from academic research and the global market. The administration routes commonly used for veterinary medicines are also explored, while special attention is given to the latest technological trends to improve the drug performance, reducing the number of doses, animal stress, and side effects. CONCLUSION Drug delivery system in veterinary decreased the number of doses, side effects, and animal stress that are a small fraction of the benefits of veterinary drug delivery systems and represent a significant increase in profit for the industry; also, it demands investments in research regarding the quality, safety, and efficacy of the drug and the drug delivery systems.
Collapse
Affiliation(s)
- Classius Ferreira da Silva
- Instituto de Ciencias Ambientais, Quimicas e Farmaceuticas, Universidade Federal de Sao Paulo, Sao Paulo, Rua Sao Nicolau, 210, Diadema - SP, CEP 09913-030, Brazil
| | - Taline Almeida
- University of Tiradentes (Unit), Av. Murilo Dantas, 300, 49010- 390, Aracaju, Brazil
| | | | | | - Margaretha Morsink
- Center for Biomedical Engineering, Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, 65 Landsdowne Street, Cambridge, Massachusetts, 02139, United States
| | - Eliana Barbosa Souto
- Faculty of Pharmacy, University of Coimbra (FFUC), Polo das Ciências da Saude, Azinhaga de Santa Comba, 3000- 548, Coimbra, Portugal
| | - Patrícia Severino
- University of Tiradentes (Unit), Av. Murilo Dantas, 300, 49010- 390, Aracaju, Brazil
| |
Collapse
|
18
|
Abuelo A, Cullens F, Brester JL. Effect of preweaning disease on the reproductive performance and first-lactation milk production of heifers in a large dairy herd. J Dairy Sci 2021; 104:7008-7017. [PMID: 33685674 DOI: 10.3168/jds.2020-19791] [Citation(s) in RCA: 22] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 01/06/2021] [Indexed: 01/14/2023]
Abstract
Raising replacement heifers represents a substantial cost in dairy farms, with reproductive efficiency being one of the main factors driving the total rearing cost. Diseases during the preweaning period, such as diarrhea or bovine respiratory disease (BRD), are reported at high incidence risks worldwide. However, the long-term effects of disease before weaning on productive and reproductive performance remain controversial. This retrospective cohort study explored the extent to which diseases such as diarrhea or BRD during the preweaning period affected average daily gain (ADG), herd removal, reproductive indices, and 305-d mature equivalent milk production (305ME) of replacement heifers. The health, growth, and production records of 2,272 female calves from a large dairy herd were used; 487 and 926 of the calves had BRD and diarrhea, respectively, before weaning. The reproductive variables age at first service, age at successful service, age at calving, and pregnancies per artificial insemination were calculated. Associations of disease status with reproduction indices, removal from herd, ADG, and 305ME were evaluated by survival analysis and mixed models. Heifers with a history of BRD before weaning were less likely to be inseminated or achieve first calving than heifers without BRD. However, BRD status did not change the age at first insemination of calving among those being inseminated or reaching first calving, respectively. There were also no differences in ADG, 305ME, and pregnancies per artificial insemination between heifers with and without a history of BRD. A history of diarrhea preweaning was not associated with changes in the probability of being inseminated, having a confirmed pregnancy, or reaching first calving. However, heifers affected by diarrhea required more inseminations to become pregnant. Diarrhea status was also associated with a 325-kg reduction in 305ME in the first lactation and a 50 g/d reduction in ADG. Collectively, our results demonstrate some long-term effects of diseases before weaning on the reproductive efficiency of heifers and first-lactation 305ME production, but with limited effect on the time to achieve critical reproductive performance indicators.
Collapse
Affiliation(s)
- Angel Abuelo
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824; Agriculture and Agribusiness Institute, MSU Extension, Michigan State University, East Lansing 48824.
| | - Faith Cullens
- Agriculture and Agribusiness Institute, MSU Extension, Michigan State University, East Lansing 48824
| | - Jill L Brester
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing 48824
| |
Collapse
|
19
|
Lees P, Pelligand L, Giraud E, Toutain PL. A history of antimicrobial drugs in animals: Evolution and revolution. J Vet Pharmacol Ther 2021; 44:137-171. [PMID: 32725687 DOI: 10.1111/jvp.12895] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/19/2019] [Revised: 06/08/2020] [Accepted: 07/06/2020] [Indexed: 12/17/2022]
Abstract
The evolutionary process of antimicrobial drug (AMD) uses in animals over a mere eight decades (1940-2020) has led to a revolutionary outcome, and both evolution and revolution are ongoing, with reports on a range of uses, misuses and abuses escalating logarithmically. As well as veterinary therapeutic perspectives (efficacy, safety, host toxicity, residues, selection of drug, determination of dose and measurement of outcome in treating animal diseases), there are also broader, nontherapeutic uses, some of which have been abandoned, whilst others hopefully will soon be discontinued, at least in more developed countries. Although AMD uses for treatment of animal diseases will continue, it must: (a) be sustainable within the One Health paradigm; and (b) devolve into more prudent, rationally based therapeutic uses. As this review on AMDs is published in a Journal of Pharmacology and Therapeutics, its scope has been made broader than most recent reviews in this field. Many reviews have focused on negative aspects of AMD actions and uses, especially on the question of antimicrobial resistance. This review recognizes these concerns but also emphasizes the many positive aspects deriving from the use of AMDs, including the major research-based advances underlying both the prudent and rational use of AMDs. It is structured in seven sections: (1) Introduction; (2) Sulfonamide history; (3) Nontherapeutic and empirical uses of AMDs (roles of agronomists and veterinarians); (4) Rational uses of AMDs (roles of pharmacologists, clinicians, industry and regulatory controls); (5) Prudent use (residue monitoring, antimicrobial resistance); (6) International and inter-disciplinary actions; and (7) Conclusions.
Collapse
Affiliation(s)
- Peter Lees
- The Royal Veterinary College, University of London, London, UK
| | | | - Etienne Giraud
- INTHERES, INRA, ENVT, Université de Toulouse, Toulouse, France
| | - Pierre-Louis Toutain
- The Royal Veterinary College, University of London, London, UK
- INTHERES, INRA, ENVT, Université de Toulouse, Toulouse, France
| |
Collapse
|
20
|
Welling V, Lundeheim N, Bengtsson B. A Pilot Study in Sweden on Efficacy of Benzylpenicillin, Oxytetracycline, and Florfenicol in Treatment of Acute Undifferentiated Respiratory Disease in Calves. Antibiotics (Basel) 2020; 9:antibiotics9110736. [PMID: 33114681 PMCID: PMC7692533 DOI: 10.3390/antibiotics9110736] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/29/2020] [Revised: 10/22/2020] [Accepted: 10/25/2020] [Indexed: 11/26/2022] Open
Abstract
Bovine respiratory disease (BRD) is a major indication for antibiotic treatment of cattle worldwide and some of the antibiotics used belong to classes of highest priority among those listed by WHO as critically important for human medicine. To preserve the efficacy of “newer” antibiotics, it has been suggested that “older” drugs should be revisited and used when possible. In this pilot study, we evaluated the efficacy of benzylpenicillin (PEN), oxytetracycline (OTC), and florfenicol (FLO) for treatment of naturally occurring BRD on two farms raising calves for slaughter. Farm personnel selected calves for enrolment, assigned calves to one of the three regimens in a systematically random manner, treated the calves, and registered the results. Overall, 117 calves were enrolled in the study. Nineteen calves relapsed in BRD before slaughter and were retreated (16.2%) and three died (2.6%). For PEN, treatment response rates after 30 days, 60 days, and until slaughter were 90.2%, 87.8%, and 80.5%, respectively; for OTC, 90.0%, 85.0%, and 85.0%, respectively; and for FLO, 86.1%, 83.3%, and 77.8%, respectively. There were no statistically significant differences in relapse, mortality, or response rates between the three treatment regimens. This indicates that PEN, OTC, and FLO were equally effective for treatment of BRD but the results need to be confirmed in a more elaborate study with a higher statistical power. The findings support the current recommendations from the Swedish Veterinary Association and the Medical Products Agency to use benzylpenicillin as a first line antibiotic for treatment of calves with undifferentiated respiratory disease in Sweden. Due to differences in the panorama of infectious agents and presence of acquired antibiotic resistance, the findings might not be applicable in other geographical areas.
Collapse
Affiliation(s)
- Virpi Welling
- Farm and Animal Health, Kungsängens Gård, SE-753 23 Uppsala, Sweden;
| | - Nils Lundeheim
- Department of Animal Breeding and Genetics, Swedish University of Agricultural Sciences, Box 7023, SE-750 07 Uppsala, Sweden;
| | - Björn Bengtsson
- Department of Animal Health and Antimicrobial Strategies, National Veterinary Institute, SE-751 89 Uppsala, Sweden
- Correspondence:
| |
Collapse
|
21
|
Pereira RV, Altier C, Siler JD, Mann S, Jordan D, Warnick LD. Longitudinal effects of enrofloxacin or tulathromycin use in preweaned calves at high risk of bovine respiratory disease on the shedding of antimicrobial-resistant fecal Escherichia coli. J Dairy Sci 2020; 103:10547-10559. [PMID: 32861496 DOI: 10.3168/jds.2019-17989] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2019] [Accepted: 05/13/2020] [Indexed: 12/26/2022]
Abstract
The objective of this study was to longitudinally quantify Escherichia coli resistant to ciprofloxacin and ceftriaxone in calves treated with enrofloxacin or tulathromycin for the control of bovine respiratory disease (BRD). Dairy calves 2 to 3 wk of age not presenting clinical signs of pneumonia and at high risk of developing BRD were randomly enrolled in 1 of 3 groups receiving the following treatments: (1) single label dose of enrofloxacin (ENR); (2) single label dose of tulathromycin (TUL); or (3) no antimicrobial treatment (control, CTL). Fecal samples were collected immediately before administration of treatment and at d 2, 4, 7, 14, 21, 28, 56, and 112 d after beginning treatment. Samples were used for qualification of E. coli using a selective hydrophobic grid membrane filter (HGMF) master grid. The ENR group had a significantly higher proportion of E. coli resistant to ciprofloxacin compared with CTL and TUL at time points 2, 4, and 7. At time point 28, a significantly higher proportion of E. coli resistant to ciprofloxacin was observed only compared with CTL. The TUL group had a significantly higher proportion of E. coli resistant to ciprofloxacin compared with CTL at time points 2, 4, and 7. None of the treatment groups resulted in a significantly higher proportion of E. coli isolates resistant to ceftriaxone. Our study identified that treatment of calves at high risk of developing BRB with either enrofloxacin or tulathromycin resulted in a consistently higher proportion of ciprofloxacin-resistant E. coli in fecal samples.
Collapse
Affiliation(s)
- R V Pereira
- Department of Population Health and Reproduction, College of Veterinary Medicine, University of California Davis, Davis 95616.
| | - C Altier
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14850
| | - J D Siler
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14850
| | - S Mann
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14850
| | - D Jordan
- New South Wales Department of Primary Industries, Wollongbar, NSW, Australia 2477
| | - L D Warnick
- Department of Population Medicine and Diagnostic Sciences, College of Veterinary Medicine, Cornell University, Ithaca, NY 14850
| |
Collapse
|
22
|
Coetzee JF, Cernicchiaro N, Sidhu PK, Kleinhenz MD. Association between antimicrobial drug class selection for treatment and retreatment of bovine respiratory disease and health, performance, and carcass quality outcomes in feedlot cattle. J Anim Sci 2020; 98:5816850. [PMID: 32255182 DOI: 10.1093/jas/skaa109] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2020] [Accepted: 04/04/2020] [Indexed: 11/14/2022] Open
Abstract
Treatment and control of bovine respiratory disease (BRD) is predicated on the use of two categories of antimicrobials, namely bacteriostatic drugs that inhibit bacterial growth and replication (STATIC), and bactericidal drugs that kill bacteria in in vitro culture systems (CIDAL). Recently, we reported that initial BRD treatment with a STATIC antimicrobial followed by retreatment with a CIDAL antimicrobial was associated with a higher frequency of multidrug-resistant bacteria isolated from field cases of BRD submitted to a veterinary diagnostic laboratory. The present study was conducted to test the hypothesis that calves administered the same class of antimicrobial for first and second BRD treatment (i.e., CIDAL-CIDAL or STATIC-STATIC) would have improved health and performance outcomes at the feedlot compared to calves that received a different antimicrobial class for retreatment (i.e., STATIC-CIDAL or CIDAL-STATIC). The association between antimicrobial treatments and health, performance, and carcass quality outcomes were determined by a retrospective analysis of 4,252 BRD treatment records from a commercial feedlot operation collected from 2001 to 2005. Data were compared using generalized linear mixed statistical models that included gender, season, and arrival weight as covariates. The mean (±SE) probability of BRD cases identified as requiring four or more treatments compared to three treatments was greater in calves that received STATIC-CIDAL (73.58 ± 2.38%) or STATIC-STATIC (71.32 ± 2.52%) first and second antimicrobial treatments compared to calves receiving CIDAL-CIDAL (50.35 ± 3.46%) first and second treatments (P < 0.001). Calves receiving CIDAL-CIDAL first and second treatments also had an increased average daily gain (1.11 ± 0.03 kg/d) compared to calves receiving STATIC-CIDAL (0.95 ± 0.03 kg/d) and STATIC-STATIC (0.84 ± 0.02 kg/d) treatments (P < 0.001). Furthermore, CIDAL-CIDAL-treated calves had a higher probability of a choice quality grade at slaughter (36.44 ± 4.80%) compared to STATIC-CIDAL calves (28.09 ± 3.88%) (P = 0.037). There was no effect of antimicrobial treatment combination on BRD mortality (P = 0.855) or yield grade (P = 0.240) outcomes. These observations suggest that consideration should be given to antimicrobial pharmacodynamics when selecting drugs for retreatment of BRD. These findings have implications for developing BRD treatment protocols that address both post-treatment production and antimicrobial stewardship concerns.
Collapse
Affiliation(s)
- Johann F Coetzee
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - Natalia Cernicchiaro
- Department of Diagnostic Medicine and Pathobiology, College of Veterinary Medicine, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - Pritam K Sidhu
- Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| | - Michael D Kleinhenz
- Department of Clinical Sciences, College of Veterinary Medicine, College of Veterinary Medicine, Kansas State University, Manhattan, KS
| |
Collapse
|
23
|
A systematic review and network meta-analysis of injectable antibiotic options for the control of bovine respiratory disease in the first 45 days post arrival at the feedlot. Anim Health Res Rev 2020; 20:163-181. [PMID: 32081117 DOI: 10.1017/s1466252320000031] [Citation(s) in RCA: 16] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/31/2022]
Abstract
We conducted a systematic review and network meta-analysis to determine the comparative efficacy of antibiotics used to control bovine respiratory disease (BRD) in beef cattle on feedlots. The information sources for the review were: MEDLINE®, MEDLINE In-Process and MEDLINE® Daily, AGRICOLA, Epub Ahead of Print, Cambridge Agricultural and Biological Index, Science Citation Index, Conference Proceedings Citation Index - Science, the Proceedings of the American Association of Bovine Practitioners, World Buiatrics Conference, and the United States Food and Drug Administration Freedom of Information New Animal Drug Applications summaries. The eligible population was weaned beef cattle raised in intensive systems. The interventions of interest were injectable antibiotics used at the time the cattle arrived at the feedlot. The outcome of interest was the diagnosis of BRD within 45 days of arrival at the feedlot. The network meta-analysis included data from 46 studies and 167 study arms identified in the review. The results suggest that macrolides are the most effective antibiotics for the reduction of BRD incidence. Injectable oxytetracycline effectively controlled BRD compared with no antibiotics; however, it was less effective than macrolide treatment. Because oxytetracycline is already commonly used to prevent, control, and treat BRD in groups of feedlot cattle, the use of injectable oxytetracycline for BRD control might have advantages from an antibiotic stewardship perspective.
Collapse
|
24
|
A systematic review and network meta-analysis of bacterial and viral vaccines, administered at or near arrival at the feedlot, for control of bovine respiratory disease in beef cattle. Anim Health Res Rev 2020; 20:143-162. [PMID: 32081122 DOI: 10.1017/s1466252319000288] [Citation(s) in RCA: 26] [Impact Index Per Article: 6.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
Vaccination against putative causal organisms is a frequently used and preferred approach to controlling bovine respiratory disease complex (BRD) because it reduces the need for antibiotic use. Because approximately 90% of feedlots use and 90% of beef cattle receive vaccines in the USA, information about their comparative efficacy would be useful for selecting a vaccine. We conducted a systematic review and network meta-analysis of studies assessing the comparative efficacy of vaccines to control BRD when administered to beef cattle at or near their arrival at the feedlot. We searched MEDLINE, MEDLINE In-Process, MEDLINE Daily Epub Ahead of Print, AGRICOLA, Cambridge Agricultural and Biological Index, Science Citation Index, and Conference Proceedings Citation Index - Science and hand-searched the conference proceedings of the American Association of Bovine Practitioners and World Buiatrics Congress. We found 53 studies that reported BRD morbidity within 45 days of feedlot arrival. The largest connected network of studies, which involved 17 vaccine protocols from 14 studies, was included in the meta-analysis. Consistent with previous reviews, we found little compelling evidence that vaccines used at or near arrival at the feedlot reduce the incidence of BRD diagnosis.
Collapse
|
25
|
How to read and interpret the results of a Bayesian network meta-analysis: a short tutorial. Anim Health Res Rev 2020; 20:106-115. [PMID: 32081116 DOI: 10.1017/s1466252319000343] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
Abstract
In this manuscript we use realistic data to conduct a network meta-analysis using a Bayesian approach to analysis. The purpose of this manuscript is to explain, in lay terms, how to interpret the output of such an analysis. Many readers are familiar with the forest plot as an approach to presenting the results of a pairwise meta-analysis. However when presented with the results of network meta-analysis, which often does not include the forest plot, the output and results can be difficult to understand. Further, one of the advantages of Bayesian network meta-analyses is in the novel outputs such as treatment rankings and the probability distributions are more commonly presented for network meta-analysis. Our goal here is to provide a tutorial for how to read the outcome of network meta-analysis rather than how to conduct or assess the risk of bias in a network meta-analysis.
Collapse
|
26
|
Comparative efficacy of antimicrobials for treatment of clinical mastitis in lactating dairy cattle: a systematic review and network meta-analysis. Anim Health Res Rev 2020; 20:229-246. [PMID: 32081123 DOI: 10.1017/s1466252319000318] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/19/2023]
Abstract
A systematic review and network meta-analysis were conducted to assess the relative efficacy of antimicrobial therapy for clinical mastitis in lactating dairy cattle. Controlled trials in lactating dairy cattle with natural disease exposure were eligible if they compared an antimicrobial treatment to a non-treated control, placebo, or a different antimicrobial, for the treatment of clinical mastitis, and assessed clinical or bacteriologic cure. Potential for bias was assessed using a modified Cochrane Risk of Bias 2.0 tool. From 14775 initially identified records, 54 trials were assessed as eligible. Networks were established for bacteriologic cure by bacterial species group, and clinical cure. Disparate networks among bacteriologic cures precluded meta-analysis. Network meta-analysis was conducted for trials assessing clinical cure, but lack of precision of point estimates resulted in wide credibility intervals for all treatments, with no definitive conclusions regarding relative efficacy. Consideration of network geometry can inform future research to increase the utility of current and previous work. Replication of intervention arms and consideration of connection to existing networks would improve the future ability to determine relative efficacy. Challenges in the evaluation of bias in primary research stemmed from a lack of reporting. Consideration of reporting guidelines would also improve the utility of future research.
Collapse
|
27
|
Hu D, O'Connor AM, Wang C, Sargeant JM, Winder CB. How to Conduct a Bayesian Network Meta-Analysis. Front Vet Sci 2020; 7:271. [PMID: 32509807 PMCID: PMC7248597 DOI: 10.3389/fvets.2020.00271] [Citation(s) in RCA: 31] [Impact Index Per Article: 7.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/11/2019] [Accepted: 04/22/2020] [Indexed: 12/11/2022] Open
Abstract
Network meta-analysis is a general approach to integrate the results of multiple studies in which multiple treatments are compared, often in a pairwise manner. In this tutorial, we illustrate the procedures for conducting a network meta-analysis for binary outcomes data in the Bayesian framework using example data. Our goal is to describe the workflow of such an analysis and to explain how to generate informative results such as ranking plots and treatment risk posterior distribution plots. The R code used to conduct a network meta-analysis in the Bayesian setting is provided at GitHub.
Collapse
Affiliation(s)
- Dapeng Hu
- Department of Statistics, Iowa State University, Ames, IA, United States
| | - Annette M. O'Connor
- Department of Large Animal Clinical Sciences, College of Veterinary Medicine, Michigan State University, East Lansing, MI, United States
| | - Chong Wang
- Department of Statistics, Iowa State University, Ames, IA, United States
- Department of Veterinary Diagnostic and Production Animal Medicine, 2203 Lloyd Veterinary Medical Center, Iowa State University, Ames, IA, United States
| | - Jan M. Sargeant
- Department of Population Medicine, University of Guelph, Guelph, ON, Canada
| | | |
Collapse
|
28
|
Brault SA, Hannon SJ, Gow SP, Warr BN, Withell J, Song J, Williams CM, Otto SJG, Booker CW, Morley PS. Antimicrobial Use on 36 Beef Feedlots in Western Canada: 2008-2012. Front Vet Sci 2019; 6:329. [PMID: 31681801 PMCID: PMC6811515 DOI: 10.3389/fvets.2019.00329] [Citation(s) in RCA: 38] [Impact Index Per Article: 7.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/29/2019] [Accepted: 09/13/2019] [Indexed: 01/21/2023] Open
Abstract
The accurate quantification of antimicrobial use (AMU) in production animals is critical for monitoring trends in exposure to antimicrobial drugs (AMD) over time and examining potential associations with antimicrobial resistance in bacteria. In this study, a census sample of cattle was used to quantify individually-dosed and in-feed AMU as both numbers of animal daily doses (nADD) and total grams of AMD (gAMD) used in cattle placed in 36 western Canadian feedlots between 1-November, 2008 and 31-October, 2012; representing about 21.5% of fed cattle in Canada during that time period. Of the ~2.6 million cattle placed during the 48-month period, 45% were calves, 63% were male, 62% arrived in the fall or winter, and 39% were assessed as high risk for developing bovine respiratory disease (BRD). The proportion of cattle categorized as high risk (HR) for developing BRD was consistent over the 4 years of placement cohorts. Both medically important AMU and ionophore use were summarized but presented separately. A decrease in AMU was observed over the study period, both as nADD and total gAMD, which was primarily driven by a decline in the in-feed administration of tetracyclines. Most in-feed AMU was directed toward prevention and control of liver abscesses. The majority of individually dosed AMU was administered as metaphylaxis to address BRD risks, with category III AMD (medium importance to human medicine as categorized by Health Canada Veterinary Drugs Directorate) used most frequently. Not surprisingly, risk level for developing BRD influenced parenteral AMD exposures, with 95% of cattle categorized as being HR for developing BRD receiving individually dosed AMD compared to 59% of cattle categorized as being low risk (LR) for developing BRD. Cattle categorized as HR for developing BRD were more likely to receive macrolides for BRD metaphylaxis compared to cattle categorized as LR for developing BRD, and cattle categorized as LR for developing BRD were more likely to receive tetracycline for the same purpose. In summary, these data provide an unprecedented representation of AMU in fed cattle in western Canada and direction for future monitoring of AMU in fed cattle.
Collapse
Affiliation(s)
- Stephanie A. Brault
- Department of Clinical Sciences, College of Veterinary Medicine & Biological Sciences, State University, Fort Collins, CO, United States
| | | | - Sheryl P. Gow
- Canadian Integrated Program for Antimicrobial Resistance Surveillance, Public Health Agency Canada, Saskatoon, SK, Canada
| | - Brian N. Warr
- Feedlot Health Management Services Ltd., Okotoks, AB, Canada
| | - Jessica Withell
- Feedlot Health Management Services Ltd., Okotoks, AB, Canada
| | - Jiming Song
- Feedlot Health Management Services Ltd., Okotoks, AB, Canada
| | | | - Simon J. G. Otto
- School of Public Health, University of Alberta, Edmonton, AB, Canada
| | | | - Paul S. Morley
- Department of Clinical Sciences, College of Veterinary Medicine & Biological Sciences, State University, Fort Collins, CO, United States
- Veterinary Education, Research and Outreach Center, Texas A&M University and West Texas A&M University, Canyon, TX, United States
| |
Collapse
|
29
|
Yang Q, Liu X, Zhang C, Yong K, Clifton AC, Ding H, Liu Y. Pharmacokinetics and Pharmacodynamics of Gamithromycin Treatment of Pasteurella multocida in a Murine Lung Infection Model. Front Pharmacol 2019; 10:1090. [PMID: 31680940 PMCID: PMC6798029 DOI: 10.3389/fphar.2019.01090] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/22/2019] [Accepted: 08/26/2019] [Indexed: 12/30/2022] Open
Abstract
Gamithromycin is approved for the treatment and prevention of bovine respiratory disease (BRD), which is caused mainly by Mannheimia haemolytica, Pasteurella multocida, Histophilus somni, and Mycoplasma species. In this study, multiple dosage regimens were administered to the neutropenic mouse lung infection model in order to investigate the pharmacokinetic/pharmacodynamic (PK/PD) parameters of gamithromycin treatment of P. multocida and to further define the PK/PD parameter that best correlates with the efficacy of gamithromycin against P. multocida. The PK characteristics of gamithromycin were analyzed after a single subcutaneous (s.c.) injection (1, 3, 6, and 9 mg/kg). The concentration–time profiles of unbound (f) gamithromycin in plasma samples were analyzed by non-compartmental analysis. The main PK parameters of gamithromycin for the area under the concentration–time curve from 0 to 24 h (f AUC0–24) and the peak drug concentration (f Cmax) values ranged from 0.86 to 8.42 µg·h/ml and from 0.55 to 5.69 µg/ml, respectively. The PD values were calculated based on multiple s.c. injections over 24 h (1, 3, 6, and 9 mg/kg at 6, 8, 12, and 24 h, respectively; total dosage 1–36 mg/ kg). The minimum inhibitory concentration (MIC) of gamithromycin against P. multocida in mice serum was 0.15 μg/ml. Analysis of PK/PD indices using the inhibitory effect Emax model indicated a strong correlation (R2 = 0.9624) between the f AUC0–24/MIC ratio and various antibacterial effects. The area under the unbound concentration–time curve over 24 h to MIC (f AUC0–24/MIC) predicted for bacteriostatic action, 1-log10 reduction, 2-log10 reduction, and 3-log10 reduction were 56.77, 90.18, 143.06, and 239.44 h, respectively. These in vivo data may facilitate gamithromycin dosage optimization against P. multocida in veterinary medicine.
Collapse
Affiliation(s)
- Qingwen Yang
- Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China.,Laboratory of Veterinary Pharmacology, Department of Animal Science and Technology, Chongqing Three Gorges Vocational College, Chongqing, China
| | - Xuesong Liu
- Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Chenghuan Zhang
- Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Kang Yong
- Laboratory of Veterinary Pharmacology, Department of Animal Science and Technology, Chongqing Three Gorges Vocational College, Chongqing, China
| | - Alancia Carol Clifton
- Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| | - Huanzhong Ding
- Laboratory of Veterinary Pharmacology, College of Veterinary Medicine, South China Agricultural University, Guangzhou, China
| | - Yun Liu
- Heilongjiang Key Laboratory for Laboratory Animals and Comparative Medicine, Department of Veterinary Surgery, College of Veterinary Medicine, Northeast Agricultural University, Harbin, China
| |
Collapse
|
30
|
Toutain PL, Sidhu PK, Lees P, Rassouli A, Pelligand L. VetCAST Method for Determination of the Pharmacokinetic-Pharmacodynamic Cut-Off Values of a Long-Acting Formulation of Florfenicol to Support Clinical Breakpoints for Florfenicol Antimicrobial Susceptibility Testing in Cattle. Front Microbiol 2019; 10:1310. [PMID: 31244816 PMCID: PMC6581757 DOI: 10.3389/fmicb.2019.01310] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/11/2019] [Accepted: 05/27/2019] [Indexed: 11/13/2022] Open
Abstract
The PK/PD cut-off (PK/PDCO) value of florfenicol for calf pathogens was determined for long acting formulations (MSD Nuflor® and a bioequivalent generic product). PK/PDCO is one of the three MICs considered by VetCAST, a sub-committee of the European Committee on Susceptibility Testing (EUCAST), to establish a Clinical Breakpoint for interpreting Antimicrobial Susceptibility Testing (AST). A population model was built by pooling three pharmacokinetic data sets, obtained from 50 richly sampled calves, receiving one of two formulations (the pioneer product and a generic formulation). A virtual population of 5,000 florfenicol disposition curves was generated by Monte Carlo Simulations (MCS) over the 96 h of the assumed duration of action of the formulations. From this population, the maximum predicted MIC, for which 90% of calves can achieve some a priori selected critical value for two PK/PD indices, AUC/MIC and T>MIC, was established. Numerical values were established for two bacterial species of the bovine respiratory disease (BRD) complex, Pasteurella multocida and Mannheimia haemolytica. It was concluded that the PK/PDCO of florfenicol for both AUC/MIC and T>MIC was 1 mg/L.
Collapse
Affiliation(s)
- Pierre-Louis Toutain
- École Nationale Vétérinaire de Toulouse, UMR 1436 Intheres INRA, Toulouse, France
- The Royal Veterinary College, Hawkshead Campus, Hatfield, United Kingdom
| | - Pritam Kaur Sidhu
- The Royal Veterinary College, Hawkshead Campus, Hatfield, United Kingdom
- Institute of Computational Comparative Medicine, College of Veterinary Medicine, Kansas State University, Manhattan, KS, United States
| | - Peter Lees
- The Royal Veterinary College, Hawkshead Campus, Hatfield, United Kingdom
| | - Ali Rassouli
- The Royal Veterinary College, Hawkshead Campus, Hatfield, United Kingdom
- Department of Comparative Biosciences, Faculty of Veterinary Medicine, University of Tehran, Tehran, Iran
| | - Ludovic Pelligand
- The Royal Veterinary College, Hawkshead Campus, Hatfield, United Kingdom
| |
Collapse
|
31
|
Abstract
Optimization of antimicrobial treatment is a cornerstone in the fight against antimicrobial resistance. Various national and international authorities and professional veterinary and farming associations have released generic guidelines on prudent antimicrobial use in animals. However, these generic guidelines need to be translated into a set of animal species- and disease-specific practice recommendations. This article focuses on prevention of antimicrobial resistance and its complex relationship with treatment efficacy, highlighting key situations where the current antimicrobial drug products, treatment recommendations, and practices may be insufficient to minimize antimicrobial selection. The authors address this topic using a multidisciplinary approach involving microbiology, pharmacology, clinical medicine, and animal husbandry. In the first part of the article, we define four key targets for implementing the concept of optimal antimicrobial treatment in veterinary practice: (i) reduction of overall antimicrobial consumption, (ii) improved use of diagnostic testing, (iii) prudent use of second-line, critically important antimicrobials, and (iv) optimization of dosage regimens. In the second part, we provided practice recommendations for achieving these four targets, with reference to specific conditions that account for most antimicrobial use in pigs (intestinal and respiratory disease), cattle (respiratory disease and mastitis), dogs and cats (skin, intestinal, genitourinary, and respiratory disease), and horses (upper respiratory disease, neonatal foal care, and surgical infections). Lastly, we present perspectives on the education and research needs for improving antimicrobial use in the future.
Collapse
|
32
|
Crosby S, Credille B, Giguère S, Berghaus R. Comparative efficacy of enrofloxacin to that of tulathromycin for the control of bovine respiratory disease and prevalence of antimicrobial resistance in Mannheimia haemolytica in calves at high risk of developing bovine respiratory disease. J Anim Sci 2018; 96:1259-1267. [PMID: 29471391 DOI: 10.1093/jas/sky054] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/14/2018] [Accepted: 02/15/2018] [Indexed: 11/13/2022] Open
Abstract
Bovine respiratory disease (BRD) is the most common cause of morbidity and mortality in North American beef cattle. Mannheimia haemolytica is the bacterial pathogen most often isolated from cattle with BRD, and the prevalence of antimicrobial resistance (AMR) in this organism has increased in recent years. Antimicrobials are commonly used to prevent BRD in cattle at high risk of developing BRD; however, recent work would suggest that this practice might be one factor contributing to the increased prevalence of AMR in M. haemolytica. We hypothesized that the administration of the short-acting fluoroquinolone, enrofloxacin, would be just as effective as the long-acting triamilide, tulathromycin, in preventing BRD but would be less likely to select for AMR M. haemolytica in stocker calves at high risk of developing BRD. Three hundred forty-one stocker calves were enrolled in the study with 172 calves in 4 pens being randomly assigned to treatment with enrofloxacin and 169 calves in 4 pens randomly assigned to treatment with tulathromycin. Calves within each treatment group were allocated to one of 4 replicate pens based on the week of enrollment. Of calves receiving enrofloxacin, 33.7% required treatment for BRD at least once within 45 d after arrival, compared with 18.3% of calves receiving tulathromycin (P = 0.040). The percentages of calves that required more than one treatment for BRD within 45 d after arrival did not differ statistically for those receiving enrofloxacin compared with those receiving tulathromycin (10.5% and 4.7%, respectively; P = 0.107) Likewise, the percentages of calves that died during the 45-d follow-up period did not differ for those receiving enrofloxacin compared with those receiving tulathromycin (12.2% and 10.1%, respectively; P = 0.592). Mannheimia haemolytica was cultured from 11% of calves sampled at arrival and from 50% of calves sampled at revaccination 14 to 17 d later. There was a significanst effect of sampling time on the proportion of calves carrying multidrug-resistant (MDR) isolates, with calves having a higher prevalence of MDR isolates at revaccination than arrival (100% vs. 13%; P < 0.001). Future research evaluating the impact of MDR on response to antimicrobial therapy is necessary.
Collapse
Affiliation(s)
- S Crosby
- Food Animal Health and Management Program, College of Veterinary Medicine, University of Georgia, Athens, GA
| | - B Credille
- Food Animal Health and Management Program, College of Veterinary Medicine, University of Georgia, Athens, GA
| | - S Giguère
- Department of Large Animal Medicine, College of Veterinary Medicine, University of Georgia, Athens, GA
| | - R Berghaus
- Food Animal Health and Management Program, College of Veterinary Medicine, University of Georgia, Athens, GA
| |
Collapse
|
33
|
Doster E, Rovira P, Noyes NR, Burgess BA, Yang X, Weinroth MD, Lakin SM, Dean CJ, Linke L, Magnuson R, Jones KI, Boucher C, Ruiz J, Belk KE, Morley PS. Investigating Effects of Tulathromycin Metaphylaxis on the Fecal Resistome and Microbiome of Commercial Feedlot Cattle Early in the Feeding Period. Front Microbiol 2018; 9:1715. [PMID: 30105011 PMCID: PMC6077226 DOI: 10.3389/fmicb.2018.01715] [Citation(s) in RCA: 40] [Impact Index Per Article: 6.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/14/2018] [Accepted: 07/09/2018] [Indexed: 02/01/2023] Open
Abstract
The objective was to examine effects of treating commercial beef feedlot cattle with therapeutic doses of tulathromycin, a macrolide antimicrobial drug, on changes in the fecal resistome and microbiome using shotgun metagenomic sequencing. Two pens of cattle were used, with all cattle in one pen receiving metaphylaxis treatment (800 mg subcutaneous tulathromycin) at arrival to the feedlot, and all cattle in the other pen remaining unexposed to parenteral antibiotics throughout the study period. Fecal samples were collected from 15 selected cattle in each group just prior to treatment (Day 1), and again 11 days later (Day 11). Shotgun sequencing was performed on isolated metagenomic DNA, and reads were aligned to a resistance and a taxonomic database to identify alignments to antimicrobial resistance (AMR) gene accessions and microbiome content. Overall, we identified AMR genes accessions encompassing 9 classes of AMR drugs and encoding 24 unique AMR mechanisms. Statistical analysis was used to identify differences in the resistome and microbiome between the untreated and treated groups at both timepoints, as well as over time. Based on composition and ordination analyses, the resistome and microbiome were not significantly different between the two groups on Day 1 or on Day 11. However, both the resistome and microbiome changed significantly between these two sampling dates. These results indicate that the transition into the feedlot-and associated changes in diet, geography, conspecific exposure, and environment-may exert a greater influence over the fecal resistome and microbiome of feedlot cattle than common metaphylactic antimicrobial drug treatment.
Collapse
Affiliation(s)
- Enrique Doster
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States
| | - Pablo Rovira
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Animal Sciences, Colorado State University, Fort Collins, CO, United States
| | - Noelle R Noyes
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Veterinary Population Medicine, University of Minnesota, St. Paul, MI, United States
| | - Brandy A Burgess
- Department of Population Health, University of Georgia, Athens, GA, United States
| | - Xiang Yang
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States
| | - Margaret D Weinroth
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Animal Sciences, Colorado State University, Fort Collins, CO, United States
| | - Steven M Lakin
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States
| | - Christopher J Dean
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States
| | - Lyndsey Linke
- Department of Clinical Sciences, Colorado State University, Fort Collins, CO, United States
| | - Roberta Magnuson
- Department of Clinical Sciences, Colorado State University, Fort Collins, CO, United States
| | - Kenneth I Jones
- Department of Biochemistry and Molecular Genetics, University of Colorado Denver School of Medicine, Aurora, CO, United States
| | - Christina Boucher
- Department of Computer and Information Science and Engineering, University of Florida, Gainesville, FL, United States
| | - Jamie Ruiz
- Department of Computer and Information Science and Engineering, University of Florida, Gainesville, FL, United States
| | - Keith E Belk
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Animal Sciences, Colorado State University, Fort Collins, CO, United States
| | - Paul S Morley
- Microbial Ecology Group, Colorado State University, Fort Collins, CO, United States.,Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO, United States.,Department of Clinical Sciences, Colorado State University, Fort Collins, CO, United States
| |
Collapse
|
34
|
Totton SC, Cullen JN, Sargeant JM, O'Connor AM. The reporting characteristics of bovine respiratory disease clinical intervention trials published prior to and following publication of the REFLECT statement. Prev Vet Med 2017; 150:117-125. [PMID: 29406078 DOI: 10.1016/j.prevetmed.2017.12.015] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2017] [Revised: 12/09/2017] [Accepted: 12/23/2017] [Indexed: 11/19/2022]
Abstract
The goal of the REFLECT Statement (Reporting guidElines For randomized controLled trials in livEstoCk and food safeTy) (published in 2010) was to provide the veterinary research community with reporting guidelines tailored for randomized controlled trials for livestock and food safety. Our objective was to determine the prevalence of REFLECT Statement reporting of items 1-19 in controlled trials published in journals between 1970 and 2017 examining the comparative efficacy of FDA-registered antimicrobials against naturally acquired BRD (bovine respiratory disease) in weaned beef calves in Canada or the USA, and to compare the prevalence of reporting before and after 2010, when REFLECT was published. We divided REFLECT Statement, items 3, 5, 10, and 11 into subitems, because each dealt with multiple elements requiring separate assessment. As a result, 28 different items or subitems were evaluated independently. We searched MEDLINE® and CABI (CAB Abstracts® and Global Health®) (Web of Science™) in April 2017 and screened 2327 references. Two reviewers independently assessed the reporting of each item and subitem. Ninety-five references were eligible for the study. The reporting of the REFLECT items showed a point estimate for the prevalence ratio >1 (i.e. a higher proportion of studies published post-2010 reported this item compared to studies published pre-2010), apart from items 10.3, i.e., item 10, subitem 3 (who assigned study units to the interventions), 13 (the flow of study units through the study), 16 (number of study units in analysis), 18 (multiplicity), and 19 (adverse effects). Fifty-three (79%) of 67 studies published before 2010 and all 28 (100%) papers published after 2010 reported using a random allocation method in either the title, abstract, or methods (Prevalence ratio = 1.25; 95% CI (1.09,1.43)). However, 8 studies published prior to 2010 and 7 studies published post-2010 reported the term "systematic randomization" or variations of this term (which is not true randomization) to describe the allocation procedure. Fifty-five percent (37/67) of studies published pre-2010 reported blinding status (blinded/not blinded) of outcome assessors, compared to 24/28 (86%) of studies published post-2010 (Prevalence ratio = 1.5, 95% CI (1.19, 2.02)). The reporting of recommended items in journal articles in this body of work is generally improving; however, there is also evidence of confusion about what constitutes a random allocation procedure, and this suggests an educational need. As this study is observational, this precludes concluding that the publication of the REFLECT Statement was the cause of this trend.
Collapse
Affiliation(s)
- Sarah C Totton
- 63 College Avenue West, Guelph, Ontario, N1G 1S1, Canada.
| | - Jonah N Cullen
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, 50011-3619, USA
| | - Jan M Sargeant
- Department of Population Medicine, Ontario Veterinary College, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada; Centre for Public Health and Zoonoses, University of Guelph, 50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada; Arrell Food Institute, University of Guelph ,50 Stone Road East, Guelph, Ontario, N1G 2W1, Canada
| | - Annette M O'Connor
- Department of Veterinary Diagnostic and Production Animal Medicine, College of Veterinary Medicine, Iowa State University, Ames, IA, 50011-3619, USA
| |
Collapse
|
35
|
Abell KM, Theurer ME, Larson RL, White BJ, Apley M. A mixed treatment comparison meta-analysis of metaphylaxis treatments for bovine respiratory disease in beef cattle. J Anim Sci 2017; 95:626-635. [PMID: 28380607 DOI: 10.2527/jas.2016.1062] [Citation(s) in RCA: 21] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
The objective of this project was to evaluate the effects of antimicrobials approved for parenteral metaphylactic use in feeder and stocker calves on morbidity and mortality for bovine respiratory disease with the use of a mixed treatment comparison meta-analysis. An initial literature review was conducted in April 2016 through Pubmed, Agricola, and CAB (Commonwealth Agricultural Bureau) for randomized controlled trials for metaphylaxis antimicrobial administered parentally to incoming feedlot or stocker calves within 48 h of arrival. The final list of publications included 29 studies, with a total of 37 trials. There were 8 different metaphylactic antimicrobials. Final event outcomes were categorized into bovine respiratory disease (BRD) morbidity cumulative incidence d 1 to ≤ 60 of the feeding period, BRD morbidity cumulative incidence d 1 to closeout of the feeding period, BRD mortality cumulative incidence d 1 to closeout of the feeding period, and BRD retreatment cumulative incidence morbidity d 1 to closeout of the feeding period. Network meta-analysis combined direct and indirect evidence for all the event outcomes to determine mean odds ratio (OR) with 95% credibility intervals (CrIs) for all metaphylactic antimicrobial comparisons. The "upper tier" treatment arms for morbidity d 1 to ≤ 60 included tulathromycin, gamithromycin, and tilmicosin. For BRD mortality cumulative incidence d 1 to closeout and BRD retreatment morbidity d 1 to closeout, classifying the treatment arms into tiers was not possible due to overlapping 95% CrIs. The results of this project accurately identified differences between metaphylactic antimicrobials, and metaphylactic antimicrobial options appear to offer different outcomes on BRD morbidity and mortality odds in feedlot cattle.
Collapse
|